key: cord-0831816-ewf0yxw6
authors: Seque, Camila Arai; Silva Enokihara, Milvia Maria Simoes E; Porro, Adriana Maria; Tomimori, Jane
title: Skin manifestations associated with COVID-19;
date: 2021-11-10
journal: An Bras Dermatol
DOI: 10.1016/j.abd.2021.08.002
sha: 7fcd4fe173fe00ce89be339c8c85f6b4d64541b2
doc_id: 831816
cord_uid: ewf0yxw6

This article will address the main aspects of skin manifestations associated with COVID-19, based on a review of the literature published to date. Since the beginning of the pandemic, more than 1,500 articles have been published on the subject. Regarding the pathophysiology, it is believed that the same mechanisms responsible for the disease in the main target organs also act in the skin, although they are not yet fully elucidated. The actual frequency of dermatological manifestations remains uncertain – it can range from 0.2% to 45%, being close to 6% in systematic reviews. Pioneering studies of large case series conducted in European countries and the USA provide the first information on the main skin manifestations associated with COVID-19 and propose classifications regarding their clinical presentation, pathophysiology, as well as their frequencies. Although there is yet no consensus, maculopapular eruptions are considered the most frequent presentations, followed by erythema pernio-like (EPL) lesions. Manifestations such as urticaria, vesicular conditions and livedo/purpura/necrosis are rare. The time of onset, severity, need for specific treatment and prognosis vary according to the clinical presentation pattern. The increasing histopathological description of skin conditions can contribute to the diagnosis, as well as to the understanding of the pathophysiology. Also, in the dermatological field, the relationship between COVID-19 and androgens has been increasingly studied. Despite all the generated knowledge, the actual biological meaning of skin manifestations remains uncertain. Therefore, the exclusion of the main differential diagnoses is essential for the correlation between skin manifestation and COVID-19.

At the beginning of the COVID-19 pandemic, skin lesions weree already considered to be important among the clinical manifestations of this new disease. Since March 2020, more than 1,500 articles correlating "dermatology" and "COVID-19" have been published. Never has such a large amount of information been generated in such a short time in the scientific community, including dermatologyrelated data. Although the first reports were poorly informative, possibly due to the inability to perform a complete dermatological examination, photographic record, histopathological and/or immunohistochemical analysis, and the scarcity of specialists in direct assistance to these patients, subsequent research has produced important contributions on the cutaneous involvement in COVID- 19 . [1] In this document, the main publications to date (04/30/21) on different aspects of the Regarding the inflammatory response, viral infections are related to the triggering of the innate and adaptive immune responses. The monocytic-macrophage system produces an exacerbated immune response, generating an intense systemic inflammatory process. The viral activation of mast cells and basophils could justify lesions such as urticaria and exanthems. [20] Regarding the vascular mechanisms, the most often studied lesions are the erythema pernio type, in analogy to the pathophysiology of previously known diseases, such as the "classic" erythema pernio (triggered by cold), "lupus", and other vascular entities, such as livedoid vasculopathy. [21] It is believed that erythema pernio associated with COVID-19 also results from an exaggerated immune reaction with signaling via type I interferon, which is important for viral eradication, but with a generalized, highly inflammatory response. In critically ill patients with purpura, vascular thrombosis in the skin and other organs would be associated with a minimal interferon response, allowing excessive viral replication, with the release of viral proteins that are located in the extrapulmonary endothelium and trigger extensive complement activation. [22, 23] Controversies regarding the pathophysiology and the presence of viral particles triggering skin lesions are based on studies that verify the absence of these particles in research, using the PCR technique in biopsies of skin lesions. [24] Additionally, it has recently been suggested that SARS-CoV-2 could cause the reactivation of other latent viruses, such as HHV-6, which is the actual responsible for some skin manifestations initially attributed to COVID-19, [25] such as exanthems and pityriasis rosealike conditions.

Soon after the first reports of isolated cases of cutaneous manifestations in patients with COVID-19, especially with the arrival of the pandemic in Europe, some countries carried out studies with national and international collaboration under the leadership of their respective academic societies. Thus, the first studies of large series of cases on the most prevalent skin manifestations were reported, including suggestions for classification into groups according to the clinical pattern and pathophysiological mechanisms. These studies were crucial for the initial understanding of the relationship between Table 3 (Large national and international series on skin manifestations).

The first large retrospective series was published on 04/29/20 by Galván-Casas et al, [26] widely publicized, containing a dermatological atlas. With support from the Spanish Academy of Dermatology, dermatologists across the country included images of skin lesions from 375 patients with COVID-19 (suspected or confirmed), which were grouped into five main patterns: maculopapular eruptions (47%), urticarial rash (19%), EPL (19%), vesico-bullous (9%), and livedo/necrosis (6%).

The most commonly found pattern was maculopapular eruptions, showing a concomitant onset with general symptoms and an average duration of 8.6 days, similarly to urticarial conditions. Both were considered not useful for the diagnosis of COVID-19 because they are non-specific manifestations common to other common conditions, such as adverse drug reactions and other viral infections.

EPL lesions occurred in younger patients with mild systemic conditions, with a late-onset (mean of 12.7 days from the onset of general symptoms) and prolonged duration. Only one of the 71 cases reported prior erythema pernio (EP). They would be useful as an epidemiological and not a diagnostic marker.

Vesicular lesions appeared before the general symptoms in 15% of the cases in this series, with a mean duration of 10.4 days and relative diagnostic specificity since they are skin manifestations not reported in viral exanthems.

Livedo/necrosis includes a variable range of presentations related to COVID-19 or its complications, such as a hypercoagulable state and vascular damage. They are associated with an older age group and higher mortality.

Although there is great merit regarding the pioneering and significant number of cases, the study limitations are the inclusion of patients who were not confirmed cases of COVID-19 (suspected cases), mostly outpatients, evaluated photographic records, without histopathological analysis or exclusion of the main differential diagnoses.

On 05/04/20, de Masson et al., [27] with support from the French Union of Dermatologists and Venereologists, published a retrospective observational study in letter form that included images of skin J o u r n a l P r e -p r o o f manifestations of 277 patients with COVID-19 (252 suspected and 25 confirmed cases) from private clinics throughout France. Surprisingly, EPL lesions corresponded to the vast majority of cases (75%) and were even reported as the single manifestation of the disease. Histopathology study carried out in three cases showed lichenoid interface dermatitis with the presence of microthrombi. Other identified cutaneous patterns were: vesicular (15%), urticarial (9%), morbilliform (9%), petechial (3%), livedo reticularis (1%), and others (15%). Some patients were accounted for in more than one category. It is worth remembering that the French were the first to describe EPL lesions related to COVID-19, which could be a bias for the high frequency shown in this study, non-reproducible in other similar studies.

Additionally, the high prevalence of EPL lesions is probably reflected in the large percentage of unconfirmed cases included in the analysis since such lesions predominate in oligo-or asymptomatic COVID-19 cases, which are seldom tested for laboratory confirmation of SARS-CoV-2 infection.

In collaboration with the American Academy of Dermatology and the International League of Dermatological Societies, Freeman et al. [28] collected data on 716 cases from 31 countries through an electronic registry and the results were published on 07/02/20. Dermatologists provided data on 54% of the cases, with 89% of all registries originating from the USA. Only 34 Hispanic/Latino and 13 African-American patients were included, impairing the racial diversity required to understand the skin manifestations. Only 171 patients were confirmed COVID-19 cases, with the following frequency of manifestations: morbilliform (22%), EPL (18%), urticarial (16%), macular erythema (13%), vesicular (11%), papulo-desquamative (9.9%) and retiform purpura (6.4%). Most of the skin manifestations started concomitantly with the general symptoms; however, in 12%, the skin lesions were the first Disease also coordinated a national study that gathered data from 200 patients with skin manifestations.

One of the inclusion criteria for Marzano et al. [29] was the presence of COVID-19-related skin lesions confirmed by an experienced dermatologist. A total of 62% had a confirmed diagnosis of COVID-19.

The main identified patterns were: maculopapular eruption/morbilliform exanthem (25.7%), EPL (24.6%), papulovesicular eruption (15.5%), urticarial eruption (10.2%), purpura/vasculitis (6.9%), livedo reticularis/racemosa (2.1%) and others (15%), which included pityriasis rosea-like, erythema multiforme-like, erythema nodosum-like, panniculitis and angioedema. Mucosal lesions were not identified. The skin condition appeared on average 14 days after the onset of systemic symptoms and lasted for an average of 12 days. EPL lesions lasted longer than the other patterns, occurred in a younger age group, and represented a lower risk of developing a severe systemic disease, all factors with statistical significance. The mean age of the livedo reticularis/racemosa and maculopapular eruption/morbilliform exanthem groups was also older (p < 0.01). One limitation of the study is the lack of diagnostic confirmation of SARS-CoV-2 infection in 36.5% of the sample due to economic factors that limited the extensive diagnostic testing in Italy and in several other countries.

Finally, the most recent population study, with very significant figures, whose results generated a lot of repercussions, was published on 01/14/21 by Visconti et al., [30] which included data from all over the United Kingdom and had a different design than those of the abovementioned publications.

The first arm of the study collected data from 336,847 users of the "COVID Symptom Study" application, in which they provided epidemiological, laboratory, and clinical information, including on the presence or absence of skin lesions identified by the users themselves. Only 2021 (7.4%) users had laboratory confirmation of COVID-19, and of these, 178 (8.8%) reported skin lesions. The prevalence was slightly higher among women. Additionally, the prevalence of skin lesions was significantly higher among those who tested positive for SARS-CoV-2 when compared to those who tested negative, justifying the inclusion of skin involvement in the list of symptoms in suspected COVID-19 infection due to its diagnostic, predictive factor, regardless of how often it occurs.

The second arm of the study sought to investigate in detail the skin manifestations through a questionnaire addressed to users who reported them and the sharing of photos. Of the 11,544 answered questionnaires, only 694 (6%) had a confirmed diagnosis of COVID-19. In this group, although the majority reported the onset of skin lesions together or soon after the general symptoms, 17% reported J o u r n a l P r e -p r o o f that the skin lesions appeared before the systemic symptoms, and in 21%, the skin condition was the only symptom. However, the study did not provide additional detailed information about these findings.

There was no description of which skin manifestations occurred prior to the general symptoms and how long before they appeared. Neither did it specify which skin lesions were considered by the individual themselves as the only manifestation of COVID-19, nor did it clarify the reason why laboratory confirmation of the disease was performed in the absence of any suspected symptoms.

In this same arm of the study, 2,328 users shared photos of skin lesions; 260 images were randomly selected for analysis by dermatologists, and of these, 30 were discarded as not attributable to To date, this is the first and only impactful publication stating the frequency and relevance of skin lesions as the only manifestation of SARS-CoV-2 infection. Therefore, caution and further studies on the subject are necessary to understand its actual importance and impact on the diagnosis of COVID-

The nature of the study has four main limitations: data based on self-assessment, not representative of the general population, disregarding of rare dermatological manifestations, and the impossibility of ruling out important differential diagnoses, such as adverse drug reactions.

There are few prospective studies on skin manifestations associated with COVID-19 that have been published to date. Such methodology would provide more reliable information about the actual prevalence of skin lesions and the identified patterns, especially through the active search for skin lesions by the specialist.

Nevertheless, different prevalence rates, proportions, and classifications of skin manifestations diagnosed by dermatologists in patients with prospectively confirmed SARS-CoV-2 infection have been reported. De Giorgi et al. [31] evaluated 678 patients in hospitals in Italy and China, finding a frequency of 7.8% of skin lesions, with 44% being identified at the diagnosis of COVID-19 and 56% in subsequent days, on average after 11.7 days. The most frequent finding was exanthem (70%), followed by urticarial (26%) and vesicular lesions (4%). All exanthem cases spontaneously improved within two to five days.

Rehktman et al. [32] evaluated 296 patients in two hospitals in New York, with an 11.8% frequency of skin lesions in the following proportions: ulcers (37.1%), purpura (25.7%), necrosis (14.3%), nonspecific erythema (11.4%), morbilliform eruption (11.4%), EPL (11.4%) and vesicles (2.9%). Méndez-Maestro et al. [33] evaluated 75 patients in a Spanish hospital, and 14 (18.7%) had skin lesions that were possibly associated with COVID-19, namely: EPL (42.8%), maculopapular eruption (28.6%), urticarial ( 14.3%), livedo reticularis-like (7.15%) and vesicular lesions (7.15%). Finally, Nuno-Gonzales et al. [34] evaluated 666 patients, also in a hospital environment in Spain, and reported a very high frequency of 45.65% of mucocutaneous lesions. However, the study included very non-specific changes that were both mucosal (examples: papillitis, glossitis, stomatitis, depapillation, mucositis) and cutaneous (examples: erythematous-brownish palmoplantar macules).

In Brazil, there are no data so far on the prevalence of skin lesions. Avancini et al. [35] reported that of the 86 patients admitted to a referral center with a confirmed infection by SARS-CoV-2 for which an evaluation by the dermatology team was requested, it was not possible to attribute a direct correlation between skin lesions and COVID-19 in any of them, since the identified profile of dermatoses was similar to that of the pre-pandemic period. Five patients had exanthem that was indistinguishable from a drug reaction, and one had EPL lesions, but together with a personal history of systemic lupus erythematosus.

A large number of publications in a short period of time allowed the first systematic review of studies on the skin manifestations of COVID-19 to appear at the end of 2020, aiming to gather and compile the results obtained up to that time, producing data with greater scientific evidence. Still, the conclusions were divergent.

In two systematic review articles, the prevalence of skin lesions in patients with COVID-19 was quite similar: 5.69 and 5.95%. [36] However, even meta-analysis studies still differ as to what would be the most frequent skin manifestations. Most systematic reviews found a higher frequency of maculopapular eruptions: 37.1%, 36% and 48%, followed by vascular lesions (including EPL): 23% and 33%. [37] However, others claim that the most common pattern would be EPL lesions (51.5%). [38] Urticarial, vesicular, and livedo/necrosis conditions are considered rarer. [36] [37] [38] In their systematic review, Jamshidi et al. [36] focused on prognostic factors associated with in 48% of cases, as well as urticarial and EPL patterns. Patients with vascular lesions of the livedo, purpura and necrosis spectrum were associated with the highest mortality (18.2%), and those with urticarial lesions, the lowest (2.2%). Regarding the time of onset of skin manifestations, the vast majority (92%) occur within four weeks of the onset of COVID-19 general symptoms, especially in the first days and up to two weeks in cases of exanthems and urticaria. On the other hand, EPL lesions occur later and appear between the second and fourth weeks, as well as purpura and necrosis. In 8 to 10% [37] of the cases, the skin manifestations may precede the clinical symptoms, on average, by three days, thus possibly being useful indicators for the early diagnosis of COVID-19. It is important to emphasize that almost all the studies included in the systematic reviews originate from Europe and the USA, with few reports from Asia and Latin America (due to the scarcity of published data), which could generate a bias.

In most studies, it is considered the most frequent skin manifestation of COVID-19. It includes exanthem (Fig. 1) , rash, diffuse papules, pityriasis rosea-like, erythema multiforme-like, among others.

It usually appears within the first days of the general viral infection symptoms or in up to two weeks, although there are sporadic reports of a late-onset (after one month). It correlates with mild systemic conditions and spontaneously improves within seven to ten days, [26] without the need for specific treatment.

Although these are frequent manifestations, they are highly non-specific, since other viral infections are common causes of exanthems, as well as adverse drug reactions. The literature discusses the need to exclude such differential diagnoses before attributing the skin condition solely to COVID-19, even in confirmed cases of the disease. Another confounding factor is the viral reactivation that occurs in cases of drug reactions, such as the activation of HHV-6 in DRESS (drug reaction with eosinophilia and systemic symptoms). One hypothesis would be that the SARS-CoV-2 infection would lead to reactivation of latent viruses, such as HHV-6, and thus predispose to an adverse drug reaction. [25, 39] J o u r n a l P r e -p r o o f

It is undeniable it are the most often reported manifestation in large case series in the literature. [40, 41] With the arrival of the COVID-19 pandemic in Europe, there was an explosion of cases similar to "classic" erythema pernio, but with peculiar characteristics, different from the classic form: infected. Immunohistochemistry and immunofluorescence studies may contribute to elucidating the relationship between EPL and COVID-19. [42] Recently, the relationship between EPL and SARS-CoV-2 infection has been widely questioned in the literature. One of the main controversies is precisely the lack of proof of SARS-CoV-2 infection in these patients. Case series of EPL have been published, which had no epidemiological, clinical, or laboratory evidence to support the diagnosis of COVID-19, [43] or even serological evidence, which could contribute to the pathophysiology of EPL. [44] Although the presence of the viral spike in EPL lesions has already been demonstrated by immunohistochemical techniques, and even the complete viral structure has been identified by electron microscopy, these were specific reports in the literature -the vast majority of publications on EPL do not have this evidence. Regarding the pathophysiology, at the beginning of the pandemic, EPL, livedo, purpura, and necrosis lesions were interpreted as phases of the same spectrum of skin involvement. It is currently believed that they have distinct pathophysiological mechanisms. [45] Page 13 of 34 J o u r n a l P r e -p r o o f

Infections, including viral ones, are known triggering factors for urticarial lesions. In this sense, SARS-CoV-2 infection could be a new triggering factor. Urticarial conditions associated with COVID-19 have been reported in patients without previous reports of the disease. A study in a private clinic reported an increased incidence of urticaria cases diagnosed during the pandemic, but no investigation was carried out regarding the presence of COVID-19 in these patients. Clinically, the lesions are disseminated, indistinguishable from other causes, and angioedema is rare. It is estimated that in 10% of patients, the skin condition may precede the general symptoms of COVID-19 by a few days, and, therefore, the detection of skin lesions could favor the early diagnosis of the infection. However, for the most part, urticarial lesions appear concomitantly with other symptoms. There is no age group predilection, and it is associated with mild systemic conditions with low mortality. Spontaneous improvement is reported within seven days or with the use of antihistamines and/or low-dose systemic corticosteroids. [46] Vesico-bullous eruptions Although rare, vesico-bullous eruptions are considered a specific pattern of skin lesion associated with COVID-19, as they are not commonly seen in viral exanthem and drug reactions (main differential diagnoses). They consist of localized or disseminated vesicles or bullae (Fig. 2) , which can affect the palmoplantar region, sparing mucous membranes. Their onset occurs approximately three days after the general symptoms and lasts for seven to 14 days, with spontaneous improvement and are associated with a mild to moderate systemic condition. In a series of cases, an attempt was made to isolate the viral agent from the bullous content using the PCR technique, without success. It is crucial to rule out other viral infections, especially herpetic ones, as a case of disseminated herpes with pneumonia has already been reported in a COVID-19 patient, showing the importance of the differential diagnosis. [47] Livedo, purpura, necrosis

The cutaneous vascular manifestations associated with COVID-19 comprise a wide spectrum, ranging from transient to fixed livedo reticularis, livedo racemosa, purpura, and necrosis of the extremities (Fig.   3 ). They are rare manifestations associated with severe systemic conditions, which occur late in elderly patients, those hospitalized in an intensive care environment, with multiple comorbidities and laboratory alterations (for example coagulopathies, elevated D-dimer levels). They are frequently associated with other thrombotic events such as deep vein thrombosis, ischemic stroke (cerebrovascular accident) and

Page 14 of 34 J o u r n a l P r e -p r o o f disseminated intravascular coagulation, which is responsible for the high mortality in this group. Therefore, skin findings in patients with a potentially fatal disease are very specific and distinct from those found in the outpatient profile. This happens because probably the same microangiopathic and thrombotic mechanisms occur simultaneously in the main target organs, such as the lung and kidneys, and in the skin. Therefore, the treatment of skin lesions consists of treating the underlying disease itself. [16, 22, 26] A summary of the main characteristics of the dermatological manifestations described above is found in Table 4 (Main characteristics of the skin manifestations associated with COVID-19).

Oral lesions during the course of COVID-19 have also been described and collected in review articles. It is known that SARS-CoV-2 can be detected in saliva using the PCR technique, which is currently used for diagnostic purposes. Moreover, ACE2, a functional viral receptor in the body, is present in the oral mucosa, with greater density on the dorsum of the tongue and minor salivary glands, which would justify the presence of mucosal lesions. Dysgeusia was the first oral symptom recognized in COVID-19, with a widely varying frequency, from five to 88%. Subsequently, numerous oral lesions were also described, with the most frequent being enanthema, petechiae, aphthoid lesions or ulcers, herpetiform lesions, candidiasis, and oral lesions associated with Kawasaki disease. They are usually symptomatic (pain, burning sensation or pruritus) and appear four days before or up to 12 weeks after the general symptoms. The treatment depends on the pattern of the lesion identified. Inadequate oral hygiene, immunosuppression, reactivation of latent viruses (for example, herpes virus), opportunistic infections, stress, trauma secondary to intubation, COVID-19 hyperinflammatory response are predisposing factors.

Further studies are required to define which oral manifestations are directly linked to SARS-CoV-2 infection and which are indirectly due to the presence of other mucosal affections that, in these cases, occur in the context of COVID-19. In this sense, research is essential to exclude such conditions. It is suggested that vascular alterations and microthrombus-induced manifestations, such as petechiae and ulcers and enanthema (similar to viral exanthem) may be directly associated with the pathophysiology of SARS-CoV-2. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Telogen effluvium and Widely known in dermatology for a long time, telogen effluvium (TE) can be triggered by metabolic, nutritional changes, drug use, and several systemic conditions, including infections. In COVID-19, it is thought that the inflammatory cytokines released and the use of medications, such as heparin, may be involved in the TE mechanism. There is a report of an increase in the incidence of TE by almost threefold during the pandemic. It is estimated that 10% of patients with COVID-19 develop TE in the weeks and months following the infection, especially in patients with comorbidities, but it can occur even in subclinical conditions. To date, information about the onset, evolution, and prognosis of TE associated with COVID-19 are indistinguishable from TE due to other known causes. There is no peculiarity or specific characteristic in TE induced by SARS-CoV-2 infection. Therefore, the approach, treatment, and follow-up of these patients should be the same adopted for TE in dermatological practice. [49, 50] Case reports

In addition to the manifestations most often described and grouped into "patterns" in the large case series, prospective and systematic review studies, there are many isolated cases reports in the literature on several skin conditions possibly associated with COVID-19. Due to the methodological limitation inherent to case report-type publications, the actual role of SARS-CoV-2 infection in these entities cannot be affirmed, that is, whether they are in fact attributable to COVID-19 or not. The isolated conditions associated with COVID-19 that have been published in case reports are shown in Table 5 (Dermatological conditions associated with COVID-19 -Case reports).

The first reports were of cases of urticaria, which even preceded clinical symptoms, [51] urticarial vasculitis, [52] and angioedema. [53] Also, cases of pityriasis rosea or pityriasis rosea-like lesions, [54] with one report showing the presence of SARS-CoV-2 by immunohistochemical techniques [55] and another pointing to the possible role of HHV-6 reactivation and other viruses in these cases. [56] There have also been reports of small-vessel vasculitis associated with COVID-19, [57] leukocytoclastic vasculitis, [58] IgA vasculitis, [59] granulomatosis with polyangiitis (formerly called Wegener's disease), [60] eosinophilic granulomatosis with polyangiitis (formerly called Churg-Strauss syndrome), [61] Schamberg purpura [62] and purpura fulminans. [63] Regarding conditions that resemble drug reactions, patients with COVID-19 and erythema multiforme have been described, [64] as well as case series of acute generalized exanthematous Page 16 of 34 J o u r n a l P r e -p r o o f pustulosis (AGEP), [65] reports of toxic epidermal necrolysis (TEN) [66] and SDRIFE (symmetrical drug-related intertriginous and flexural exanthem). [67] There are also case reports in specific topographiesungual involvement, with a description of the "red half-moon sign"; [68] palmoplantar involvement with erythrodysesthesia; [69] follicular eruption, [70] unilateral exanthem, [71] unilateral livedo reticularis [72] and pressure ulcers in unusual locations (such as the sternum, knees) from prolonged pronation. [73] Dermoscopic descriptions of purpuric papular eruption [74] and EPL lesions have been published. [75] There are also reports of herpes zoster [76] and isolated reports of Grover's disease-like conditions, [77] Melkersson-Rosenthal syndrome, [78] erythema nodosum, [79] sarcoid lesion, [80] Gianotti-Crosti syndrome, [81] seborrheic dermatitis, [82] annular lichen planus, [83] erythema annulare centrifugum, [84] granuloma annulare [85] and rapidly progressive alopecia areata. [86] 

Some studies presented the first descriptions of histopathological and immunohistochemical changes in skin lesions associated with COVID-19, aiming to contribute to the understanding of the pathophysiological mechanisms of these manifestations. The main histopathological changes of the most often described skin patterns will be briefly mentioned below.

[87]

Superficial perivascular dermatitis with mild lymphocytosis, thrombosed vessels with neutrophilic and eosinophilic debris; interface dermatitis, superficial and deep perivascular lymphocytic infiltrate, with or without vasculitis (Fig. 4) .

In the epidermis, presence of parakeratosis and hyperkeratosis, with apoptotic keratinocytes and, eventually, epidermal necrosis. Dense lymphocytic infiltrate in the superficial and deep dermis, also in the hypodermis, with a perivascular pattern and signs of endothelial activation. Sometimes, eccrine lymphocytic infiltrate is similar to that seen in eccrine lymphocytic hidradenitis. Other common findings are erythrodiapedesis, edema in the papillary dermis with the formation of a subepidermal bulla and increased interstitial mucin deposition. The presence of vascular microthrombi in the capillaries of the superficial dermis is rare, a well as in dermal venules.

Perivascular lymphocytic infiltrate with some eosinophils and edema in the superficial dermis, eventually with vacuolar interface dermatitis and keratinocyte necrosis, with a pattern similar to that of erythema multiforme. In urticarial vasculitis, there is extravasation of red blood cells with perivascular neutrophilic infiltrate, macrophages, necrosis, and fibrin deposits.

Acanthosis, vesicles due to vacuolar degeneration of the basal layer with dyskeratotic, multinucleated cells (suggestive of viral inclusion) without inflammatory infiltrate. In these cases, the differential diagnosis with herpetic dermatoviruses is essential.

Thrombotic vasculopathy with extensive deposition of C5b-9 and C4d (immunohistochemical technique) in the microvasculature.

Throughout the pandemic, SARS-CoV-2 infection was observed to affect more men than women. Men are twice as likely to be admitted to intensive care units. The association between the androgen pathway and SARS-CoV-2 infectivity has been described. Therefore, such predisposition to androgen-mediated infection could justify the high rates of hospitalization and mortality concentrated in men. Therefore, androgen expression in the form of alopecia (androgenetic alopecia -AGA) could, by itself, be a risk factor for COVID-19, and a high frequency of AGA has been reported among hospitalized men; and also the use of anti-androgens could be a protective and/or therapeutic factor in the evolution of these patients. In this sense, a published study showed that men with AGA or benign prostatic hyperplasia using a 5-alpha-reductase inhibitor who contracted COVID-19 showed a significant reduction in symptoms in the outpatient setting. In a case-control study in a hospital setting, men using 5-alpha- The pandemic has provided an excellent opportunity for dermatologists to learn and contribute.

Unfortunately, it is not over yet. As science is a dynamic process, there is hope that more studies will be carried out so that answers can be found and uncertainties can be resolved.

None declared. 

The first report in the literature of a skin manifestation associated with COVID-19 occurred on 03/23/20. Since then, there have been more than 1,500 publications on the subject.

The frequency of skin manifestations ranges from 0.2% to 45%, being close to 6% in systematic review studies

The most frequently described manifestations are maculopapular eruptions, followed by the erythema pernio-like (EPL) lesions Urticarial, vesicular and the livedo-purpura-necrosis spectra are less frequent Skin lesions usually accompany the general symptoms. However, urticaria and vesicles may precede them, while EPL lesions and livedo-purpura-necrosis appear later.

The main differential diagnoses are drug reactions and other viral infections, which should be ruled out. 

Dermatology and COVID-19

COVID-19 can present with a rash and be mistaken for dengue

Clinical Characteristics of Coronavirus Disease 2019 in China

Cutaneous manifestations in COVID-19: a first perspective

Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature

Skin manifestations in COVID-19: The tropics experience

Cutaneous symptoms of patients diagnosed with COVID-19 in one province: a cross-sectional survey

COVID-19 skin eruptions: incidence in hospitalized patients in Bologna

Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome

Three cases of COVID-19 patients presenting with erythema

Lack of skin manifestations in COVID-19 hospitalized patients during the second epidemic wave in Spain: a possible association with a novel SARS-CoV-2 variant a cross sectional study

Belda Junior W. Potential interactions of SARS-CoV-2 with human cell receptors in the skin: Understanding the enigma for a lower frequency of skin lesions compared to other tissues

Cutaneous manifestations of SARS-CoV-2 a two-center, prospective, case-controlled study

Angiotensinconverting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)

SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

Cutaneous manifestations in COVID-19: Lessons learned from current evidence

Lessons from dermatology about inflammatory responses in Covid-19

Pernio during the COVID-19 pandemic and review of inflammation patterns and mechanisms of hypercoagulability

The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series

COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient

Absence of SARS-CoV-2 RNA detection in tissue samples of COVID-19-related cutaneous lesions analyzed by real-time RT-PCR

COVID-19-associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role?

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France

The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries

The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients

Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection

Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy

Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19

Skin manifestations in patients hospitalized with confirmed COVID-19 disease: a cross-sectional study in a tertiary hospital

Prevalence of mucocutaneous manifestations in 666 patients with COVID-19 in a field hospital in Spain: oral and palmoplantar findings

Absence of specific cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 in a reference center in Brazil

Skin Manifestations in COVID-19 Patients: Are They Indicators for Disease Severity? A Systematic Review

Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review

Dermatologic manifestations of COVID-19: a comprehensive systematic review

Exanthem and eosinophilia in COVID-19 patients: has viral infection a role in drug induced exanthems?

Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak

Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries

COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases

Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing

Do we have serological evidence that chilblain-like lesions are related to SARS-CoV-2? A review of the literature

Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned

Urticaria and COVID-19: A review

Varicellalike exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients

Oral manifestations of COVID-19 disease: A review article

SARS-CoV-2-induced telogen effluvium: a multicentric study

ethnicity and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID-19 pandemic

Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom?

Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature

Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: A report of 2 cases

SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease

Widespread cutaneous small vessel vasculitis secondary to COVID-19 infection

Leucocytoclastic vasculitis in a patient with COVID-19 with positive SARS-CoV-2 PCR in skin biopsy

Possible association between IgA vasculitis and COVID-19

New Onset Granulomatosis with Polyangiitis Associated with COVID-19

Eosinophilic granulomatosis with polyangiitis mimicking coronavirus disease 2019: a case report

Schamberg-like purpuric eruptions and tonsillitis in mild COVID-19

Purpura fulminans as the presenting manifestation of COVID-19

Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2

Acute Generalized Exanthemtous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia

Development of toxic epidermal necrolysis in a coronavirus disease 2019 patient with recurrence of positive SARS-CoV-2 viral RNA

SDRIFE-like rash associated with COVID-19, clinicopathological correlation

The red half-moon nail sign: a novel manifestation of coronavirus infection

Palmoplantar erythrodysesthesia: a diagnostic sign of COVID-19

Follicular eruption as a cutaneous manifestation in COVID-19

Unilateral laterothoracic exanthem in association with coronavirus disease 2019

Unilateral livedo reticularis in a COVID-19 patient: Case with fatal outcome

Pression-induced facial ulcers by prone position for COVID-19 mechanical ventilation

Papular-purpuric exanthem in a COVID-19 patient: clinical and dermoscopic description

Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients

Herpes zoster ophthalmicus in COVID-19 patients

Grover-like skin eruption: another cutaneous manifestation in a COVID-19 patient

Melkersson-Rosenthal Syndrome Induced by COVID-19

Erythema nodosum-like rash in a COVID-19 patient: A case report

Sarcoid-like reaction in a patient recovering from coronavirus disease 19 pneumonia

An Isolated Peculiar Gianotti-Crosti Rash in the Course of a COVID-19 Episode

Seborrheic dermatitis in COVID-19: a case report

Annular lichen planus associated with coronavirus SARS-CoV-2 disease (COVID-19)

Erythema annulare centrifugum with anosmia and ageusia in a SARS-CoV-2 exposed patient successfully treated with doxycycline

Granuloma annulare triggered by SARS-CoV-2 infection: Immunohistochemical staining

COVID-19: association with rapidly progressive forms of alopecia areata